Review links LL-37 and MRGPRX2 mast-cell signaling to rosacea lesions
Authors say human tissue work localizes MRGPRX2 to lesional mast cells, but no study has yet tested the receptor selectively in rosacea patients.
PR
By Priya Raman · Science Reporter
Oct 6 20:00 ETSource: Clinical, cosmetic and investigational dermatology
The wire
- 01A narrative review in Clinical, Cosmetic and Investigational Dermatology collates human tissue, mast-cell and mouse data on LL-37 driving MRGPRX2-mediated calcium signaling and degranulation in rosacea.
- 02LL-37 is tracked closely on this beat, and the review frames MRGPRX2 as a candidate drug target downstream of the cathelicidin pathway already implicated in rosacea.
- 03The authors note human MRGPRX2 and mouse MrgprB2 are pharmacologically distinct, receptor and patient findings come from separate settings, and direct selective testing in patients is still lacking.
From the source
Read at pubmed.ncbi.nlm.nih.govLL-37-MRGPRX2-Mast Cell Signaling in Rosacea: Current Evidence and Directions for Human Studies
Clinical, cosmetic and investigational dermatology · 2026 · Yin H, Lu Y et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42861262/
